AZNAstraZenecaSigning up patients
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Gastroesophageal Adenocarcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 100 (planned)
- Started
- Jul 17, 2025
- Main results expected
- Nov 9, 2027
- Fully finished
- Jul 16, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Measured over: Until sub-study completion, up to 38 months
Percentage of participants with pathological complete response (pCR)
Measured over: Until sub-study completion, up to 38 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07069712 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC